HCV New Drugs

This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.

Risk Of Developing Liver Cancer After HCV Treatment

▼

Showing posts with label Liver cancer CF102. Show all posts

Showing posts with label Liver cancer CF102. Show all posts

Thursday, March 2, 2017

Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis

New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis - Phase II trial to treat NAFLD/NASH...

Thursday, September 17, 2015

FDA Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer

U.S. Food and Drug Administration Grants Fast Track Designation to Can-Fite's CF102 in the Treatment of Liver Cancer PETACH TIKVA, Isr...

Wednesday, April 30, 2014

Can-Fite Submits Protocol to U.S. FDA for Phase II Liver Cancer Study

Can-Fite Submits Protocol to U.S. FDA for Phase II Liver Cancer Study Tufts University will be a clinical site for international trial of C...

Tuesday, January 3, 2012

Results:CF102 in the treatment of hepatocellular carcinoma (HCC).

Can-Fite BioPharma Announces Successful Results of its Phase I/II Liver Cancer Study with its CF102 Drug; the Study Achieved the Primary and...

Friday, May 13, 2011

CF102 Drug; Interim Analysis Data Phase I/II Liver Cancer Study

Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, a...

View web version

Powered by Blogger.